Background. Myelosuppression due to pegylated interferon (peg-IFN) is common during treatment for hepatitis C virus. The relationship between infection risk and decreases in leukocyte lines, however, is not well established. The objective of this analysis was to determine the incidence of and risk factors for infections during peg-IFN/ribavirin (RBV) therapy.
Interferon alfa has been used to treat chronic hepatitis C virus (HCV) infection since the early 1990s and remains the backbone of many treatment regimens involving HCV protease inhibitors [1] [2] [3] . Interferon alfa, however, has many side effects, including cytopenias [1] . When patients are treated with one of the longacting, pegylated formulations of interferon, pegylated interferon (peg-IFN) alfa-2a, or peg-IFN alfa-2b, in combination with ribavirin (RBV) for up to 48 weeks, the incidence of severe neutropenia, defined as an absolute neutrophil count (ANC) of <0.5 × 10 9 cells/L, ranges from 4% to 12% [4, 5] . Furthermore, more modest declines in ANC to <0.75 × 10 9 cells/L have been reported in up to 30% of patients [4, 5] . Due to concern for increased infection risk in the setting of neutropenia, the prescribing information for both approved peg-IFN products recommends peg-IFN dose reduction and discontinuation in patients with ANC <0.75 × 10 9 cells/L and <0.5 × 10 9 cells/L, respectively [4, 5] . These treatment modifications are not without consequence; they have been associated with a decreased likelihood of achieving sustained virologic response (SVR) [6] [7] [8] .
In this context, the relationship of neutropenia and incident infection during treatment with peg-IFN-based HCV therapy has been extensively investigated. The risk of infection associated with severe neutropenia due to chemotherapy among cancer patients and recipients of hematopoietic cell transplants is well established; however, most studies have not demonstrated any increased infection risk among patients who develop neutropenia while receiving peg-IFN [6, [9] [10] [11] [12] [13] [14] . Nevertheless, up to 23% of patients develop acute infections during HCV treatment [6, [10] [11] [12] [13] [14] . The risk factors for acute infection, particularly clinically severe infections, have not been fully established in these relatively small studies [6, [10] [11] [12] [13] [14] . Because of the large number of patients treated with peg-IFN (>3000) and the breadth of data collected, the Individualized Dosing Efficacy vs Flat Dosing to Assess Optimal Pegylated Interferon Therapy (IDEAL) study provides a unique opportunity to evaluate the incidence of and risk factors associated with acute infections among patients receiving HCV treatment with peg-IFN/RBV, with an emphasis on understanding the relationship between treatment-induced cytopenias and infection [15] .
METHODS

Study Design
The IDEAL study has been described in detail elsewhere [15] . In brief, this was a phase 3, randomized, parallel-group, US multicenter study of peg-IFN alfa-2b 1.5 µg/kg/week or 1.0 µg/kg/ week or peg-IFN alfa-2a 180 µg/week combined with ribavirin (RBV) for the treatment of chronic HCV infection. Persons aged 18-70 years weighing 40-125 kg were eligible if they had compensated liver disease due to HCV genotype 1 infection and were treatment naive. The primary endpoint was SVR, defined as an undetectable HCV RNA level 24 weeks after stopping therapy.
Setting and Participants
Demographic data, vital signs, height, weight, medical history, physical examination, medication use, tobacco use, and depression assessment via the Center for Epidemiologic Studies Depression (CES-D) scale were performed and/or collected at screening. Laboratory testing included complete blood count, chemistry panel, antinuclear antibodies, serum pregnancy test, HCV RNA level, and HCV genotype. Liver biopsy performed within 3 years of treatment was required. Patients were required to meet eligibility criteria consistent with standard HCV treatment guidelines: white blood cell (WBC) count ≥3.0 × 10 9 cells/L; ANC ≥1.5 × 10 9 cells/L; platelet count ≥80 × 10 9 /L; hemoglobin (Hb) level ≥12 g/dL for women and ≥13 g/dL for men; normal serum creatinine and thyroid stimulating hormone; no known human immunodeficiency virus or hepatitis B virus infection; fasting glucose level 70-140 mg/dL (and if 116-140 mg/dL or if diabetic, HbA1C ≤8.5%); absence of moderate and severe psychiatric disorders and/or recent substance abuse; and absence of uncontrolled medical conditions such as obesity (weight >125 kg) and clinically significant heart disease. Patients with chronic obstructive pulmonary disease and/or immunologically mediated diseases (eg, inflammatory bowel disease or systemic lupus erythematosus) were excluded.
Data Collection
Patients were evaluated at weeks 2, 4, 8, 12, 18, 24, 30, 36, 42 , and 48 after initiating therapy, and then at weeks 4, 12, and 24 after discontinuing therapy. Complete blood counts were performed during each of these visits, as were vital signs and blood chemistries. During each visit, patients were queried about signs and/or symptoms suggestive of adverse events (AEs). The CES-D scale was performed at baseline and at weeks 2, 4, 12, 24, 36, and 48.
Safety and Adverse Events
All AEs were recorded, and the severity was assessed by the investigator according to modified World Health Organization recommendations. Actions or outcomes (eg, hospitalization) resulting from AEs were recorded. Clinical assessments and/or laboratory evaluations were performed as appropriate until resolution or stabilization of any AE. When indicated, medication dose reductions were performed according to the product label for each agent. While receiving reduced medication doses, patients were evaluated every 2 weeks until the AE resolved or they stabilized. Treatment medications were discontinued permanently in the event of any life-threatening AE. Dose reductions were required for grade 3 leukopenia (WBC <1.5 × 10 9 cells/L), grade 3 neutropenia (ANC <0.75 × 10 9 cells/L), anemia (Hb <10 g/dL), or grade 3 thrombocytopenia ( platelet count <50 × 10 9 /L); permanent treatment discontinuation was required for grade 4 leukopenia (WBC <1.0 × 10 9 /L), grade 4 neutropenia (ANC <0.5 × 10 9 cells/L), Hb <8.5 g/dL, or grade 4 thrombocytopenia ( platelet count <25 × 10 9 /L). Use of granulocyte colony-stimulating factor and/or granulocyte-macrophage colony-stimulating factor was prohibited. In conjunction with appropriate medication dose reductions, erythropoietin use was permitted for management of incident anemia at the discretion of the individual investigator. Treatment modification for lymphocytopenia was not recommended or required.
Infections were defined by the examining clinician as mild (resulting in awareness of the otherwise easily tolerated infection), moderate (resulting in discomfort interfering with usual activities and potentially warranting intervention), severe ( precluding usual activities, significantly affecting clinical status, and warranting intervention), or life-threatening (major infection with hypotension). Patients who developed mild depression were monitored weekly for 4-8 weeks; no medication dosing changes were required. Patients who developed moderate depression were required to undergo dose reduction per the prescribing information for each agent, and weekly monitoring was instituted. Medications were discontinued for any patient with worsening or severe depression.
Statistical Analysis
Categorical variables were summarized using proportions, and continuous variables were summarized using means, medians, and standard deviations. A logistic regression model using a stepwise selection method with baseline demographic characteristics and on-treatment minimum hematologic parameters was used to identify variables independently associated with incident infections. P values for comparison are presented based on the χ 2 -test for categorical variables or the t test for continuous variables. Odds ratios (ORs) and 95% confidence intervals (CIs), with P values, were also reported using logistic regression.
All P values reported are nominal P values and have not been adjusted for multiple comparisons. All statistical analyses were done using SAS software, version 9.3.
The study was approved by each center's institutional review board and was conducted in accordance with provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. Each patient provided informed consent for participation in the study.
RESULTS
Incident Infections
Incident infection of any severity was reported in 1092 of 3070 (35.6%) patients treated with peg-IFN/RBV for up to 48 weeks. The majority of these patients sustained infections classified by their treating physician as mild (n = 511; 46.8% of 1092 patients with incident infections) or moderate (n = 520, 47.6%); 55 (5.0%) and 6 (0.5%) infections were classified as severe or life-threatening, respectively. No pathogen was identified for 443 of 581 (76.2%) patients who sustained 550 episodes of infection of at least moderate severity; most of these infections involved the respiratory tract. A pathogen was culture confirmed or clinically suspected in 200 patients (34.4%) who sustained 210 episodes of moderate, severe, and life-threatening infections. (The sum of these percentages equals >100% because some patients developed >1 infection.) Among the identified pathogens, influenza viruses, herpes viruses, Staphylococcus species, and Candida species were most commonly reported (Supplementary Table 1 ). The 6 life-threatening infections were Escherichia sepsis, blastomycosis, appendicitis, infective tenosynovitis, pneumonia, and sepsis.
Baseline Patient Characteristics and Incident Infections
Patients' baseline demographic and clinical characteristics according to severity of incident infection are shown in Table 1 . When considering moderate, severe, and life-threatening infections, women were more likely than men to have ear infections (2.3 vs 1.2 infections per 100 person-years), lower respiratory tract and lung infections (6.5 vs 4.0), upper respiratory tract infections (12.7 vs 6.4), and urinary tract infections (4.8 vs 0.6) (Supplementary Table 2 ). The incidence of moderate, severe, and life-threatening infections did not differ significantly between patients treated with low-dose (17.3%) and standarddose (18.0%) peg-IFN alfa-2b; the incidence was 21.4% among patients treated with peg-IFN alfa-2a. The incidence did not vary significantly according to patient age, histologic disease stage, or mean baseline neutrophil and lymphocyte counts.
On-Treatment Neutrophil and Lymphocyte Counts and Incident Infections
The mean maximum decline from baseline and the mean nadir ANC and absolute lymphocyte count (ALC) for all patients with at least 1 on-treatment complete blood cell profile are shown in Table 2 . The incidence of infection varied according to the nadir on-treatment ANC ( Table 3 ). A total of 648 patients (21%) treated with peg-IFN had an ANC <0.75 × 10 9 cells/L; of these patients, 12 (0.4%) developed a severe or life-threatening infection, and only 1 had sepsis that was considered to be treatment related ( Figure 1A ). Severe and life-threatening infections were observed at a similar frequency in each ANC category, including those with ANC >1.0 × 10 9 cells/L (incidence, 2.2%) and those with ANC <1.0 × 10 9 cells/L (incidence, 1.7%). The incidence of infection also varied according to the nadir ontreatment absolute lymphocyte count (Table 4 ). Of the 107 with a nadir ALC <0.5 × 10 9 cells/L, only 34 also had a nadir ANC <0.75 × 10 9 /L ( Table 5 and Figure 1B and 1C ). For subjects who had post-baseline ALC and ANC values and a known date of infection, subjects were significantly more likely to have progressively lower ALCs in advance of infections of increasing severity (P = .01; Supplementary Table 3 ). No such relationship was demonstrated for ANCs in advance of infections. Table 6 ). As expected based on the study protocol, peg-IFN dose modifications were common among subjects who sustained grade 3-4 neutropenia, regardless of incident infections ( Supplementary Table 4 ). Whereas subjects who had grade 3-4 lymphocytopenia and either no or mild infections were more likely to have peg-IFN dose modifications than were subjects with grade 0-2 lymphocytopenia, no such trends were apparent among subjects who developed infections of at least moderate severity (Supplementary Table 5 ). The relationship of the nadir ALC and sex and history of depression are shown in Figure 2 . After adjustment for other covariates, peg-IFN type (alfa-2a or alfa-2b) and nadir ANC were not associated with incident moderate, severe, or life-threatening infections.
DISCUSSION
In this large, prospective cohort of HCV genotype 1-infected patients treated with peg-IFN alfa plus RBV, we did not detect an independent association between incident infection and neutropenia. Further, we identified novel factors-namely, treatment-related lymphocytopenia and female sex-associated with incident infections. These findings have important implications for the management of patients during HCV treatment that includes peg-IFN alfa. First, although neutropenia was common, with 648 (21%) of patients experiencing an ANC <0.75 × 10 9 cells/L, the majority of clinically significant infections were not temporally associated with neutropenia. Furthermore, after adjustment for other factors, including lymphocytopenia and sex, nadir on-treatment ANC was not associated with such infections. These observations support previously published studies that did not demonstrate an association between neutropenia and incident infection [6, 10, [12] [13] [14] . When also considering the lack of association between peg-IFN dose reductions and reduced rates of incident infection [6, 13] , these data suggest that IFN-related neutropenia is not strongly associated with infection risk. Despite these findings, in our study and those previously reported, the dose of peg-IFN alfa was reduced in patients with ANCs below a defined level, typically 0.75 × 10 9 cells/L; the safety of lower ANC thresholds for peg-IFN dose reduction was not evaluated. To date, one study, VIRAHEP-C (Viral Resistance to Antiviral Therapy of Chronic Hepatitis C), incorporated a strategy of continuing full-dose peg-IFN alfa-2a in patients with ANC >0.5 × 10 9 cells/L and did not report a higher than expected rate of infections [16] . Although this study supports the use of a lower ANC threshold for peg-IFN dose reduction, additional studies are needed to confirm this revised approach to treatment-related neutropenia.
Second, independent of neutropenia, we identified a strong relationship between treatment-induced lymphocytopenia and incident infection. In prior HCV treatment studies with IFN alfa, lymphocytopenia was consistently observed. In clinical studies of peg-IFN alfa-2a for treatment of HCV infection described in the US prescribing information, for example, lymphocytopenia of any grade was reported in 81% and 91% of patients treated with monotherapy and combination therapy with RBV, respectively; severe lymphocytopenia (<0.5 × 10 9 cells/L) was observed in 5% and 14% of those treated with monotherapy and combination therapy with RBV, respectively [4] . Although RBV appeared to contribute to the lymphocytopenia in these studies, we were not able to assess the impact, if any, of RBV on incident lymphocytopenia in our study because all patients took RBV. While 1 case of a patient developing reactivation pulmonary tuberculosis in the setting of peg-IFN and RBV-associated lymphocytopenia has been reported, the clinical significance of HCV treatment-induced lymphocytopenia has not been previously described in a large patient cohort [17] . Our data suggest that lymphocytopenia may be an important marker of increased risk for moderate, severe, or life-threatening infections. Although our data do not permit assessment of causation and therefore cannot compel a recommendation for peg-IFN dose reduction for lymphocytopenia, our finding suggests that clinicians should monitor the ALC (in addition to ANC) carefully during treatment. Future studies of peg-IFN, as well as those Third, we found a 61% increased risk of infection among women, predominantly as a result of an increased frequency of upper respiratory and genitourinary tract infections, as well as fungal or Candida infections. The relationship between sex and infection was independent of lymphocytopenia. The underlying mechanism for this observed increased risk is not known, although an increased incidence of urinary tract and Candida infections (eg, vulvovaginal candidiasis) among women is not unexpected; as such, these sex discordances may not be directly related to HCV treatment. The increased incidence of clinically diagnosed upper respiratory tract infections (URTIs) is more difficult to characterize as we are unable to determine the criteria by which such infections were diagnosed; clinical diagnoses were at the provider's discretion. Women may be more likely to present to medical attention with URTIs of at least moderate severity, such that sex differences in clinical presentation led to bias in ascertainment and classification of URTIs by treating clinicians. Although additional studies are needed, clinicians should be aware of the increased infection incidence in women treated with peg-IFN/RBV. Last, we found an increased incidence of infection in patients with a clinical history of baseline depression. Interestingly, the risk of infection did not correlate with baseline CES-D score or occurrence of depression during treatment. This finding may be explained by differences in reporting of infectious symptoms between patients with a history of depression compared to those without such a history; it may, however, also point to the interplay between depression or psychological stress, innate immune function, and IFN [18] [19] [20] . Of interest, whereas leukopenia is not a common side effect of antidepressant medications, some agents, such as bupropion, have been associated with leukopenia.
Our study has several limitations. First, as noted above, most infections were diagnosed by individual clinicians on the basis of clinical presentation. In general, detailed microbiological and other related data were not reported. The possibility that some reported infections were noninfectious or were misclassified by pathogen and/or organ system cannot be excluded. These limitations, however, are present in most studies of outpatient infections; in practice, respiratory and other infections are routinely diagnosed on clinical grounds alone. A related limitation is that infection severity was also judged by individual clinicians; what one clinician may have judged as mild, another may have assessed as moderate. This limitation seems less likely, however, to have affected assessments of severe or life-threatening infections. We also did not capture information on therapeutic management of diagnosed infections. Second, because the treatment protocol mandated peg-IFN dose reductions for incident neutropenia, we were unable to fully characterize the association between infection and declines in ANC and ALC; these peg-IFN dose reductions led to increases in ANC and ALC. This limits the ability to understand the effect of prolonged ANC suppression. Third, laboratory data were not always collected contemporaneously with incident infections; we therefore cannot be certain, for example, about a temporal relationship between lymphocytopenia and diagnosed infection. Where these data were available, however, there was a relationship between lower nadir ALC and incident infections of greater severity.
In summary, moderate, severe, or life-threatening infections were common in HCV-infected adults treated with peg-IFN/ RBV for up to 48 weeks, occurring in 19% of patients. In this cohort of 3070 patients, infectious complications were associated with reductions in the ALC rather than the ANC. This observation has important implications for the management of patients treated with peg-IFN/RBV alone or in combination with other agents. Although further research is needed to confirm this observation, clinicians should carefully monitor the ALC in addition to the ANC for patients receiving HCV therapy with peg-IFN and/or RBV.
